Bortezomib-induced acute neutrophilic dermatosis

作者：Tanguy Schmidt A; Avenel Audran M; Croue A; Lissandre S; Dib M; Zidane Marinnes M; Moles M P; Hunault Berger M^*

来源：Annales de Dermatologie et de Venereologie, 2009, 136(5): 443-446.

DOI：10.1016/j.annder.2008.11.021

• Bortezomib
• Sweet Syndrome
• Neutrophilic dermatosis
• Drug eruption

Introduction. - Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological, and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients.
Case Report. - We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present.
Discussion. - The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence.

• 出版日期2009-5